TRIUMPH-1 to TRIUMPH-4 Readouts: Quantitative Analysis of Retatrutide’s Phase 3 Weight-Loss Trajectories
Retatrutide, Eli Lilly’s investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, has generated substantial clinical interest following its Phase 2 readouts, which demonstrated unprecedented weight loss magnitudes in adults with obesity. The Phase 3 TRIUMPH programme represents a pivotal step in translating these early signals into regulatory-grade evidence. This analysis examines the quantitative weight-loss trajectories emerging from the TRIUMPH-1 and TRIUMPH-4 readouts, placing them in the broader context of the retatrutide clinical development programme. TRIUMPH-1: The Flagship Obesity Trial TRIUMPH-1 is the foundational Phase 3 study in the retatrutide obesity programme. This randomised, double-blind, placebo-controlled trial enrolled 2,339 adults with obesity or overweight without diabetes, including prespecified subsets with knee osteoarthritis and obstructive sleep apnoea. Participants received once-weekly subcutaneous retatrutide at 4...
